Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Lateral Flow Immunoassay Developed for Melioidosis

By Labmedica International staff writers
Posted on 03 Apr 2014
Print article
Image: The Gram-negative aerobic bacteria Burkholderia pseudomallei grown on sheep blood agar for 96 hours (Photo courtesy of Larry Stauffer).
Image: The Gram-negative aerobic bacteria Burkholderia pseudomallei grown on sheep blood agar for 96 hours (Photo courtesy of Larry Stauffer).
A lateral flow immunoassay that can be used in the clinical setting to diagnose melioidosis in 15 minutes has been developed and the test promises to provide improved management of patients with the disease.

Isolation of Burkholderia pseudomallei, a soil-dwelling bacterium and the causative agent of melioidosis, from clinical samples is the “gold standard” for the diagnosis of melioidosis, but this can take as long as three days to a week to produce the results.

Scientists at InBios International, Inc., (Seattle, WA, USA) and a team of international colleagues, have developed a rapid point-of-care antigen detection assay for the diagnosis of melioidosis. A diagnostic immunoassay based on the detection of B. pseudomallei capsular polysaccharide (CPS) was investigated. Following production of a CPS-specific monoclonal antibody (mAb), an antigen-capture immunoassay was developed to determine the concentration of CPS within a panel of melioidosis patient serum and urine samples.

The same mAb was used to produce a prototype Active Melioidosis Detect Lateral Flow Immunoassay (AMD LFI) and the limit of detection of the LFI for CPS is comparable to the antigen-capture immunoassay, approximately 0.2 ng/mL. LFIs were read after 15 minutes and determined to be positive or negative based on the presence or absence of a pink-red line at the test line in the presence of a positive control line. The analytical reactivity or inclusivity of the AMD LFI was 98.7% (76/77) when tested against a large panel of B. pseudomallei isolates. Analytical specificity or cross-reactivity testing determined that 97.2% of B. pseudomallei near neighbor species (35/36) were not reactive.

The authors concluded that when the LFI is used to test urine, sputum, and pus, high sensitivity will be achieved due to the increased colony forming units (CFU)/mL values in these matrices. The LFI is currently being evaluated in Thailand and Australia and the focus is to optimize and validate testing procedures on melioidosis patient samples prior to initiation of a large, multisite preclinical evaluation. The study was published on March 20, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

InBios International Inc.



Print article

Channels

Genetic Tests

view channel

Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis

Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases. MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression... Read more

Lab Tech.

view channel

Method Preserves Microfluidic Devices for HIV Monitoring in Developing Countries

Microfluidic devices with immunochemistry have broad applications in chemotherapy monitoring, transplant patient monitoring, and especially in monitoring the efficacy of antiretroviral therapy. Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.